Wegovy History & Development: From GLP-1 Discovery to FDA Approval

The Biology That Made Wegovy Possible

Wegovy did not emerge from a weight-loss program. It emerged from decades of basic science aimed at type 2 diabetes, and that origin shapes everything about how the drug works.

Discovery of GLP-1 and the Incretin Effect

In the early 1980s, researchers studying the incretin effect noticed that oral glucose triggered far more insulin release than the same glucose given intravenously. The peptide responsible for a large share of that effect was isolated in 1983 and named glucagon-like peptide-1 (GLP-1) [1]. GLP-1 is secreted by intestinal L-cells within minutes of eating and acts on GLP-1 receptors in the pancreas, brain, gut, heart, and adipose tissue.

The problem for drug developers was that native GLP-1 has a plasma half-life of roughly 1 to 2 minutes because the enzyme dipeptidyl peptidase-4 (DPP-4) degrades it almost immediately [2]. A therapeutic molecule had to resist that degradation.

From Exendin-4 to Long-Acting Analogs

The first GLP-1 receptor agonist approved by the FDA was exenatide (Byetta, 2005), derived from a peptide found in Gila monster saliva that is naturally resistant to DPP-4. Twice-daily injections limited its appeal. Liraglutide (Victoza, 2010) came next: Novo Nordisk attached a fatty acid chain to native GLP-1, allowing albumin binding that extended the half-life to roughly 13 hours and permitted once-daily dosing [3].

Semaglutide was the next logical step. Novo Nordisk's chemists made two key modifications to the liraglutide backbone. First, they substituted alanine at position 8 with aminoisobutyric acid (Aib), blocking DPP-4 cleavage entirely. Second, they attached a longer, more complex C-18 fatty diacid chain via a linker, maximizing albumin affinity and extending the half-life to approximately 7 days. That 7-day half-life is the structural reason weekly dosing works [4].

GLP-1 Receptors in the Brain: The Weight-Loss Signal

Appetite regulation became central to semaglutide's story once researchers mapped GLP-1 receptors in the hypothalamus and brainstem. Specifically, GLP-1 receptors in the arcuate nucleus and the nucleus tractus solitarius receive satiety signals from the gut and respond by reducing food intake and slowing gastric emptying [5].

At the 2.4 mg dose used in Wegovy (compared with the 1 mg dose approved for diabetes as Ozempic), the central satiety signal is substantially stronger. Dose-finding studies showed that appetite suppression and body-weight reduction continued to rise across the 0.5 mg to 2.4 mg dose range without a clear plateau, which is why Novo Nordisk pursued a higher-dose obesity indication.

The Semaglutide Development Timeline

Understanding Wegovy requires tracing semaglutide through its full development arc, starting with its diabetes origins.

Oral and Injectable Semaglutide for Diabetes (2012 to 2017)

Novo Nordisk filed an investigational new drug application for semaglutide around 2012 and initiated a large cardiovascular outcomes trial called SUSTAIN-6 (N=3,297) to satisfy FDA requirements under the 2008 cardiovascular safety guidance for antidiabetic drugs. SUSTAIN-6, published in the New England Journal of Medicine in 2016, showed that subcutaneous semaglutide 0.5 mg and 1 mg reduced the rate of major adverse cardiovascular events (MACE) by 26% versus placebo in people with type 2 diabetes at high cardiovascular risk (HR 0.74; 95% CI 0.58 to 0.95; P<0.001 for non-inferiority) [6].

The FDA approved Ozempic (semaglutide 0.5 mg and 1 mg for type 2 diabetes) in December 2017. An oral formulation (Rybelsus, 14 mg) followed in September 2019.

The Strategic Decision to Pursue Obesity

During the SUSTAIN program, secondary endpoint analyses revealed that semaglutide produced weight loss far exceeding that seen with earlier GLP-1 receptor agonists at approved doses. Participants receiving semaglutide 1 mg in SUSTAIN-1 through SUSTAIN-5 lost 3.6 to 6.5 kg over 30 to 56 weeks [7]. Those numbers were clinically meaningful but not dramatic. Dose-escalation modeling suggested that pushing to 2.4 mg could roughly double the weight-loss effect in people without diabetes.

Novo Nordisk launched the STEP (Semaglutide Treatment Effect in People with Obesity) program specifically to characterize a 2.4 mg subcutaneous weekly dose for chronic weight management. The program comprised four key trials and several supportive studies.

STEP Program: The Four Key Trials

STEP-1 enrolled 1,961 adults with a BMI of 30 or higher (or 27 or higher with at least one weight-related comorbidity) but without type 2 diabetes. At 68 weeks, semaglutide 2.4 mg produced a mean weight loss of 14.9% versus 2.4% with placebo (difference: 12.4 percentage points; 95% CI 11.5 to 13.4; P<0.001) [8]. Approximately 86.4% of semaglutide participants lost at least 5% of body weight versus 31.5% on placebo.

STEP-2 (N=1,210) tested the 2.4 mg dose specifically in adults with type 2 diabetes. Mean weight loss was 9.6% at 68 weeks versus 3.4% placebo [9]. The attenuated response in people with diabetes was consistent with what had been seen across GLP-1 agonist programs.

STEP-3 (N=611) added an intensive behavioral intervention to semaglutide and showed a mean weight loss of 16.0% at 68 weeks, suggesting that lifestyle support amplifies the drug effect [10].

STEP-4 (N=902) used a 20-week run-in phase in which all participants received semaglutide 2.4 mg, then randomized them to continue semaglutide or switch to placebo. Those who continued lost an additional 7.9% of body weight by week 68, while those switched to placebo regained 6.9%. The trial demonstrated that the drug effect requires ongoing treatment [11].

FDA Review and the June 2021 Approval

Novo Nordisk submitted the New Drug Application for semaglutide 2.4 mg to the FDA in October 2020. The FDA's Endocrinologic and Metabolic Drugs Advisory Committee did not convene a formal advisory committee meeting for Wegovy, citing sufficient data from the STEP program. The agency approved Wegovy on June 4, 2021, making it the first drug approved specifically for chronic weight management in adults since lorcaserin was withdrawn in 2020 [12].

Approved Indication and Label Specifics

The FDA-approved label covers adults with an initial BMI of 30 kg/m² or higher, or 27 kg/m² or higher with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. The dose escalation schedule starts at 0.25 mg weekly for 4 weeks, increases by 0.25 mg every 4 weeks, and reaches the 2.4 mg maintenance dose at week 17. In June 2023, the FDA extended the approval to adolescents aged 12 and older based on the STEP Teens trial (N=201), which showed 16.1% mean body-weight reduction versus 0.6% placebo at 68 weeks [13].

The Boxed Warning and Risk Considerations

The Wegovy label carries a boxed warning for thyroid C-cell tumors based on rodent carcinogenicity studies showing dose-dependent thyroid C-cell hyperplasia and tumors at clinically relevant exposures. The FDA notes that "the human relevance of these rodent findings has not been determined" but contraindicates Wegovy in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [12].

Other clinically significant adverse effects include pancreatitis, gallbladder disease, and the class-wide concern about heart rate elevation. The most common adverse events in STEP-1 were gastrointestinal: nausea (44% semaglutide vs. 16% placebo), diarrhea (30% vs. 16%), vomiting (24% vs. 6%), and constipation (24% vs. 11%) [8].

Mechanism of Action at the Molecular Level

Semaglutide binds to and activates the GLP-1 receptor, a class B G-protein-coupled receptor. Receptor activation triggers cyclic AMP production, leading to glucose-dependent insulin secretion from pancreatic beta cells, suppression of glucagon from alpha cells, and slowing of gastric emptying. At the doses used in Wegovy, the dominant clinical effect shifts from glycemic control toward appetite suppression mediated by central GLP-1 receptors.

Central Appetite Suppression

Positron emission tomography studies and functional MRI work in humans confirmed GLP-1 receptor expression in the hypothalamus, amygdala, and brainstem. Semaglutide reduces the hedonic response to food cues detectable on functional MRI, specifically blunting activation in reward-processing regions in response to high-calorie food images [14]. This is why patients commonly report that food is "less interesting" rather than simply feeling full.

Peripheral Effects on Gastric Emptying

By slowing gastric emptying, semaglutide prolongs the sensation of fullness after meals. This peripheral effect also blunts postprandial glucose excursions. At 2.4 mg, the gastric emptying delay is meaningful but does not produce the gastroparesis-level impairment that has been reported anecdotally with higher off-label doses.

Body Composition Effects

A secondary analysis of STEP-1 using dual-energy X-ray absorptiometry data found that the majority of weight lost with semaglutide was fat mass. Lean mass declined proportionally, which is consistent with the degree of weight loss rather than a drug-specific effect. Preservation of lean mass relative to total weight lost with semaglutide appeared comparable to or slightly better than caloric restriction alone at similar magnitudes of weight reduction.

The SELECT Trial and Cardiovascular Indication

The SELECT trial (N=17,604) enrolled adults with established cardiovascular disease and overweight or obesity but without type 2 diabetes. The primary endpoint was a composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. Results published in the New England Journal of Medicine in November 2023 showed that semaglutide 2.4 mg reduced the primary MACE endpoint by 20% versus placebo (HR 0.80; 95% CI 0.72 to 0.90; P<0.001) over a median follow-up of 33.6 months [15].

The FDA approved an additional indication for Wegovy in March 2024: reduction of the risk of cardiovascular death, myocardial infarction, and stroke in adults with established cardiovascular disease and BMI of 27 kg/m² or higher. This approval made Wegovy the first weight-loss drug in history to carry a cardiovascular risk reduction label.

The SELECT data created what the HealthRX clinical team describes as a "dual-indication decision framework" for patients with obesity and cardiovascular disease: the prescriber can now justify Wegovy on cardiovascular risk reduction grounds independent of the weight-loss target, which changes the reimbursement conversation with payers and aligns the drug more closely with statins and antihypertensives in the cardiovascular prevention stack.

Manufacturing Challenges and Supply Constraints

Wegovy launched commercially in the United States in October 2021 but encountered severe supply shortages by early 2022. Novo Nordisk cited unexpected demand surpassing manufacturing capacity at its fill-and-finish facilities. The company invested approximately 40 billion Danish krone (roughly $5.7 billion USD) in manufacturing expansion between 2021 and 2024, including new facilities in Kalundborg, Denmark, and expanded contract manufacturing partnerships.

The FDA listed Wegovy on its drug shortage database in 2022 and maintained that listing through portions of 2023 and 2024 at various dose strengths. The shortage affected clinical practice directly: prescribers reported patients unable to complete dose escalation, which may have reduced efficacy and increased gastrointestinal side effects when patients re-initiated at lower doses after gaps.

Competitive Context: Where Semaglutide Sits

Tirzepatide (Zepbound, 15 mg), Eli Lilly's dual GIP/GLP-1 receptor agonist, received FDA approval for obesity in November 2023. The SURMOUNT-1 trial (N=2,539) showed a mean weight loss of 20.9% at 72 weeks with tirzepatide 15 mg versus 3.1% placebo [16]. Head-to-head comparative data do not yet exist from a prospective randomized trial, but the SURMOUNT and STEP datasets suggest tirzepatide may produce greater weight loss at maximum approved doses.

Retatrutide (triple GIP/GLP-1/glucagon agonist), orforglipron (oral small-molecule GLP-1 agonist), and CagriSema (semaglutide plus cagrilintide amylin analog) are in phase 3 development. Each represents an attempt to push mean weight loss beyond 20 to 25%, a threshold that would approach the efficacy of bariatric surgery.

Despite that competitive pressure, semaglutide 2.4 mg remains the most extensively studied obesity pharmacotherapy in history by number of trial participants and breadth of outcomes data, including cardiovascular, renal, and metabolic endpoints.

Clinical Use in Practice

The 17-week dose escalation schedule serves two purposes. It minimizes gastrointestinal adverse effects during the adjustment period, and it allows the prescriber to assess tolerability before committing to the maintenance dose. Patients who cannot tolerate the 2.4 mg dose may remain at 1.7 mg, the penultimate dose step, though label efficacy data are anchored at 2.4 mg.

Injection Technique and Storage

Wegovy is supplied in single-dose prefilled pens. Patients inject subcutaneously into the abdomen, thigh, or upper arm. Rotation among sites reduces local reactions. Pens should be stored in a refrigerator at 36 to 46 degrees Fahrenheit and can be kept at room temperature (up to 86 degrees Fahrenheit) for up to 28 days once in use.

Drug Interactions and Contraindications

Semaglutide slows gastric emptying and may reduce the rate, though not the overall extent, of absorption of orally administered drugs. Patients on narrow-therapeutic-index oral medications, including levothyroxine and warfarin, should have those levels monitored more frequently in the first several months of Wegovy treatment. Wegovy is contraindicated during pregnancy. Women of reproductive potential should use effective contraception, as weight loss itself may restore ovulation in women with obesity-related anovulation.

Monitoring Recommendations

The American Association of Clinical Endocrinology (AACE) 2023 obesity algorithm recommends assessing weight, blood pressure, heart rate, and HbA1c (in patients at risk for diabetes) at 4, 12, and 24 weeks after initiation, then every 6 months during maintenance [17]. Lipase levels are not routinely monitored but should be checked if a patient develops persistent severe abdominal pain.

The American Gastroenterological Association recommends holding GLP-1 receptor agonists for at least 7 days before elective procedures requiring general anesthesia due to the risk of aspiration from delayed gastric emptying, though that interval is based on expert consensus rather than randomized data [18].